What is the recommended treatment for protracted bacterial bronchitis in a child with a chronic wet cough?

Management of Protracted Bacterial Bronchitis in Children

For a child with chronic wet cough (>4 weeks duration) and no specific warning signs, initiate a 2-week course of amoxicillin-clavulanate at 25-35 mg/kg twice daily as first-line treatment. 1

Initial Clinical Assessment

Before prescribing antibiotics, confirm the following:

• Chronic wet cough present for >4 weeks without resolution 1
• Absence of "cough pointers" that mandate immediate investigation rather than empiric antibiotics 1:
  • Digital clubbing (suggests chronic lung disease or bronchiectasis)
  • Coughing with feeding (suggests aspiration)
  • Failure to thrive
  • Hemoptysis
  • Abnormal chest radiograph

If any cough pointers are present, proceed directly to investigations (flexible bronchoscopy, chest CT, immunologic testing) rather than empiric antibiotics. 1, 2

First-Line Antibiotic Therapy

Amoxicillin-clavulanate is the preferred antibiotic because it covers the three most common PBB pathogens: Haemophilus influenzae (nontypeable), Streptococcus pneumoniae, and Moraxella catarrhalis. 1, 2

• Dosing: 25-35 mg/kg orally twice daily 1, 2
• Initial duration: 2 weeks (Grade 1A recommendation) 1
• Alternative antibiotics (clarithromycin, erythromycin, cefaclor) have been used but amoxicillin-clavulanate remains first-line 1

Response Assessment and Next Steps

If Cough Resolves Within 2 Weeks:

• The diagnosis of PBB is confirmed (Grade 1C) 1
• No further investigations are needed 1, 2
• Monitor for recurrence, as recurrent PBB (>3 episodes/year) increases bronchiectasis risk 3

If Wet Cough Persists After 2 Weeks:

Extend the same antibiotic for an additional 2 weeks (total 4 weeks of treatment). (Grade 1C) 1

This approach balances antimicrobial stewardship with the minority of children requiring longer therapy. 1, 2 A recent RCT found that while 4-week courses did not significantly improve cure rates at day 28 compared to 2-week courses, they did result in significantly longer time to next wet cough exacerbation (median 150 vs 36 days). 4

If Wet Cough Persists After 4 Weeks of Appropriate Antibiotics:

Proceed to further investigations (Grade 2B) 1, 2:

• Flexible bronchoscopy with quantitative cultures and sensitivities to identify specific pathogens and guide targeted therapy 1, 2
• Chest CT scan to evaluate for bronchiectasis—children whose cough persists after 4 weeks have markedly increased likelihood of CT-diagnosed bronchiectasis (adjusted OR 5.9; 95% CI 1.2-28.5) 1, 2
• Immunologic evaluation to assess for immunodeficiency 1, 2
• Assessment for chronic aspiration if clinically indicated 1, 2

Microbiological Considerations

• When bronchoscopy is performed, ≥10⁴ CFU/mL of respiratory bacteria in bronchoalveolar lavage defines "microbiologically-based PBB" (PBB-micro) to differentiate from clinically-based PBB 1, 2
• The most common pathogens are H. influenzae (nontypeable), S. pneumoniae, and M. catarrhalis 1, 2, 3
• Staphylococcus aureus has been reported in some retrospective studies but without quantitative testing 1

Critical Pitfalls to Avoid

• Do not prescribe courses shorter than 2 weeks—prospective studies support a minimum 2-week duration for effective treatment 1, 5, 6
• Do not delay investigations beyond 4 weeks of failed antibiotic therapy—this increases the risk of missing underlying bronchiectasis or other serious pathology 1, 2
• Do not misdiagnose PBB as asthma—this is the most common misdiagnosis in primary care, leading to inappropriate steroid use rather than antibiotics 7
• Do not use third-generation cephalosporins or macrolides as first-line—these are less appropriate than amoxicillin-clavulanate for typical PBB pathogens 8

Evidence Quality and Nuances

The CHEST guidelines provide Grade 1A evidence for 2-week amoxicillin-clavulanate as initial therapy, with high-quality RCT data showing significant benefit (number needed to treat = 3). 1, 5, 6 The recommendation to extend to 4 weeks if needed is Grade 1C, reflecting lower-quality evidence but strong clinical consensus. 1 The 2021 DACS trial found no significant difference in cure rates between 2-week and 4-week courses at day 28, but the 4-week group had longer cough-free periods, suggesting some children benefit from extended therapy. 4